Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients

Journal of Affective Disorders

Volumn 47, Issue 1-3, 1998, Pages 55-62

  Feighner, John P ^a   Entsuah, A Richard ^b   McPherson, M K ^b  

^a Feighner Research Institute   (United States)

^b WYETH AYERST RESEARCH   (United States)

Author keywords

Anxiety; Extended release; Major depression; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SUSTAINED RELEASE PREPARATION; SYMPTOMATOLOGY; VERTIGO; XEROSTOMIA;

ADULT; AMBULATORY CARE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; COHORT STUDIES; COMORBIDITY; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0031909995     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(97)00109-2     Document Type: Article

References (35)

1. Benkert, O., Gründer, G., Wetzel, H., Hackett, D., 1996. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J. Psychiatr. Res. 30, 441-451.
2. Clayton, P.J., Grove, W.M., Coryell, W., Keller, M., Hirschfeld, R., Fawcett, J., 1991. Follow-up and family study of anxious depression. Am. J. Psychiatry 148, 1512-1517.
3. Clerc, G.E., Ruimy, P., Verdeau-Pailles, J., 1994. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int. Clin. Psychopharmacol. 9, 138-143.
4. Cunningham, L.A., Borison, R.L., Carman, J.S. et al., 1994. A comparison of venlafaxine, trazodone, and placebo in major depression. J. Clin. Psychopharmacol. 14, 99-106.
5. Cunningham, L.A. (Venlafaxine XR 208 Study Group), 1997. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. Ann. Clin. Psychiatry 9, 157-164.
6. Depression Guideline Panel. Depression in Primary Care: Vol. 2. Treatment of Major Depression. Clinical Practice Guideline, No. 5. Rockville, MD. US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 93-0551, April 1993.
7. Dierick, M., Ravizza, L., Realini, R., Martin, A., 1996. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog. Neuropsychopharmacol. Biol. Psychiatry 20, 57-71.
8. Dornseif, B.E., Dunlop, S.R., Potvin, J.H., Wernicke, J.F., 1989. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol. Bull. 25, 71-79.
9. Dunner, D.L., Dunbar, G.C., 1992. Optimal dose regimen for paroxetine. J. Clin. Psychiatry 53 (Suppl.), 21-26.
10. Entsuah, R., Upton, G.V., Rudolph, R., 1995. Efficacy of venlafaxine treatment in depressed patients with psychomotor retardation or agitation: A meta-analysis. Hum. Psychopharmacol. 10, 195-200.
11. Fawcett, J., 1990. Targeting treatment in patients with mixed symptoms of anxiety and depression. J. Clin. Psychiatry 51 (Suppl. 11), 40-43.
12. Fawcett, J., Scheftner, W.A., Fogg, L. et al., 1990. Time-related predictors of suicide in major affective disorder. Am. J. Psychiatry 147, 1189-1194.
13. Filteau, M.J., Baruch, P., Lapierre, Y.D., Bakish, D., Blanchard, A., 1995. SSRIs in anxious-agitated depression: A post hoc analysis of 279 patients. Int. Clin. Psychopharmacol. 10, 51-54.
14. Guelfi, J.D., White, C., Hackett, D., Guichoux, J.Y., Magni, G., 1995. Effectiveness of venlafaxine in patients hospitalized with major depression and melancholia. J. Clin. Psychiatry 56, 450-458.
15. Gullick, E.L., King, L.J., 1979. Appropriateness of drugs prescribed by primary care physicians for depressed outpatients. J. Affect. Disord. 1, 55-58.
16. Hamilton, M.A., 1960. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23, 56-62.
17. Johnstone, E., Cunningham-Owens, D.G., Firth, C.D. et al., 1980. Neurotic illness: Its response to anxiolytic and antidepressant treatment. Psychol. Med. 10, 321-328.
18. Khan, A., Rudolph, R., Baumel, B., Ferguson, J., Ryan, P., Shrivastava, R., 1995. Venlafaxine in depressed geriatric outpatients: An open-label clinical study. Psychopharmacol. Bull. 31, 753-758.
19. Lecrubier, Y., Bourin, M., Moon, C.A.L. et al., 1997. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr. Scand. 95, 485-493.
20. Liebowitz, M.R., 1993. Depression with anxiety and atypical depression. J. Clin. Psychiatry 54 (Suppl. 2), 10-14.
21. Montgomery, S.A., Asberg, M., 1979. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382-389.
22. Muth, E.A., Haskins, J.T., Moyer, J.A., Husbands, G.E., Nielsen, S.T., Sigg, S.B., 1986. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol. 35, 4493-4497.
23. Nutt, D., 1995. The anxiety factor in depression. J. Psychopharmacol. 9 (Suppl.), 185-189.
24. Preskorn, S.H., Lane, R.M., 1995. Sertraline 50 mg: Optimal dose in the treatment of depression. Int. Clin. Psychopharmacol. 10, 129-141.
25. Rudolph, R., Entsuah, R., Chitra, R., 1995. The effects of venlafaxine on anxiety associated with depression. 2nd International Conference on New Directions in Affective Disorders, Jerusalem, September 3-8, p. 79.
26. Schatzberg, A.F., 1995. Fluoxetine in the treatment of comorbid anxiety and depression. J. Clin. Psychiatry Monograph 13(2), 12.
27. Schweizer, E., Feighner, J., Mandos, L., Rickels, K., 1994. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J. Clin. Psychiatry 55, 104-108.
28. Sheehan, D., Dunbar, G.C., Fuell, D.L., 1992. The effect of paroxetine on anxiety and agitation associated with depression. Psychopharmacol. Bull. 28, 139-143.
29. Shrivastava, R., Cohn, C., Crowder, J. et al., 1994. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J. Clin. Psychopharmacol. 14, 322-329.
30. Stavrakaki, C., Vargo, B., 1986. The relationship of anxiety and depression: A review of the literature. Br. J. Psychiatry 149, 7-16.
31. Thase, M.E. (Venlafaxine XR 209 Study Group), 1997. Efficacy and tolerability of once-daily venlafaxine extended release (XRER) in outpatients with major depression. J. Clin. Psychiatry 58, 393-398.
32. Tollefson, G.D., Breist, J.H., Jefferson, J.W. et al., 1994. Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: A comparative trial of fluoxetine and imipramine. J. Clin. Psychopharmacol. 14, 385-391.
33. Tollefson, G.D., Holman, S.L., Sayler, M.E., Potvin, J.H., 1994. Fluoxetine, placebo and tricyclic antidepressants in major depression with and without anxious features. J. Clin. Psychiatry 55, 50-59.
34. Tylee, A., Beaumont, G., Bowden, M.W., Reynolds, A. (General Practice Study Group) 1984. A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Primary Care Psychiatry 3, 51-58.
35. Van Valkenberg, C., Akiskal, H.S., Puzantian, V., Rosenthal, T., 1984. Anxious depressions: Clinical, family history, naturalistic outcome: Comparisons with panic and major depressive disorders. J. Affect. Disord. 6, 67-82.